Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)

NCT07219953 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07219953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
October 16, 2025
Completion date
April 30, 2028
Enrollment
1,100 (estimated)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder